Navigation Links
Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
Date:7/9/2008

SOUTH SAN FRANCISCO, Calif., July 9 /PRNewswire/ -- Portola Pharmaceuticals, Inc., a privately-held biotechnology company focused on the discovery and development of novel therapeutics for cardiovascular and inflammatory diseases, announced today that is has raised $60 million in a preferred stock financing. Proceeds will be used primarily to advance Portola's two lead antithrombotic clinical candidates, betrixaban and PRT060128, which the company is developing as best-in-class compounds to replace existing standards of care. In addition, funds will be used to develop the company's pre-clinical pipeline including its novel Factor Xa inhibitor antidote, which has the potential to expand the use of anticoagulants. New investors, including D.E. Shaw group, Adage Capital Management, BBT Capital Management/Apothecary Capital, Janus Capital Group and PAC-LINK BioVentures, joined the company's existing investors to complete the round.

"Raising funds from this outstanding group of investors in this challenging market validates the potential value of our novel product candidates for thrombosis, one of the world's largest markets," said Charles Homcy, M.D., president and chief executive officer of Portola. "These funds will also help us advance a novel Factor Xa inhibitor antidote and our Syk and JAK inhibitor program, which further diversify the company's pipeline and may offer opportunities for accelerated product development."

Two Clinical Candidates Address Global Thrombosis Market

Portola is advancing two differentiated drug candidates that address the global, multi-billion dollar antithrombotic market where existing drugs, such as enoxaparin (Lovenox(R)), clopidogrel (Plavix(R)) and warfarin (Coumadin(R)), have well known limitations.

Betrixaban, the company's first Phase 2 drug candidate, is an oral Factor Xa inhibitor. Factor Xa is a validated target for which there are approved drugs on the market, and inhibiting its activity is bel
'/>"/>

SOURCE Portola Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pulmo BioTech Inc. Completes Bio-Distribution Studies
2. Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. Metabolex Completes Patient Enrollment in Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
5. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
6. Pharmaxis Long-Term Safety Study of Bronchitol Completes
7. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
8. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
9. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
10. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
11. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... LONDON , December 24, 2014 ... grow at an average rate of 8.1%. The US ... Hip, knee and spine surgeries are the common orthopedic ... they have a lower penetration. Increased number of product ... composites. Non-metallic orthopedic devices have gained popularity in the ...
(Date:12/24/2014)... , Dec. 23, 2014  Advanced Medical Isotope ... engaged primarily in the development of brachytherapy devices ... today announced that it has filed a ... Drug Administration ("FDA") for marketing clearance for its ... of the U.S. Food, Drug and Cosmetic Act ...
(Date:12/24/2014)... Dec. 23, 2014   Synageva BioPharma Corp. ... company developing therapeutic products for rare disorders, today ... of the Marketing Authorization Application (MAA) for sebelipase ... the company,s request for accelerated assessment, which has ... time.   The MAA, and the ...
Breaking Medicine Technology:Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
... Endothelial Dysfunction, Conference Call and Webcast to ... CET), NOVATO, Calif., Oct. 15 BioMarin,Pharmaceutical ... from its Phase,2a multi-center, open-label, dose-escalation clinical study ... designed to evaluate whether 6R-BH4,can improve the endothelial ...
... for physicians, NATICK, Mass. and WASHINGTON, Oct. ... today announced results from an analysis,of the HORIZONS ... the,Cardiovascular Research Foundation (CRF) with research grant support ... MDCO ) is designed to,determine the safety and ...
Cached Medicine Technology:BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease 2BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease 3BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease 4BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease 5BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease 6HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients 2HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients 3HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients 4
(Date:12/25/2014)... 2014 Plugin creators from Pixel Film ... fully customizable business presentation tool made specifically for ... 5k business tool, users can now display their stats ... Pixel Film Studios. “ProFire 5k gives users a multiple ... professionalism to a presentation” , Pixel Film Studios takes ...
(Date:12/25/2014)... 2014 Each year trauma accounts for ... hospital admissions across the nation (according to the ... CDC’s National Hospital Ambulatory Medical Care Survey collected ... in 2010. They estimated that there were between 3.5 ... a primary diagnosis of broken bone or fracture. ...
(Date:12/24/2014)... AlignLife of Wauwatosa loves helping ... items. During the holiday season, AlignLife looks forward to their ... says Dr. Sara Mahalko-Leonhardt, owner of AlignLife. "It brings our ... that we are able to give kids toys for Christmas ... for the generosity of our patients." , The 70 toys ...
(Date:12/24/2014)... Epigenetics finds applications in a large number of fields ... biology, and research for metabolic and genetic disorders. It ... used techniques for the discovery and development of cancer ... rapidly growing worldwide. In 2012, there were 14.1 million ... million people living with cancer (within five years of ...
(Date:12/24/2014)... Recently, iFitDress.com, a famous dress manufacturer and retailer, ... $150 . All these items are brand new; they are ... been updated with the new range of high quality prom ... All iFitDress.com’s designs are made according to the latest trends. ... Every outfit from the company is handpicked by skilled tailors. ...
Breaking Medicine News(10 mins):Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Many Prom Dresses under 150 from Well-known Dress Manufacturer iFitDress.com 2
... The American Dietetic Association commended Congress and ... State Children,s Health Insurance Program into law.The $32.6 ... President Bush in 2007, expands government health coverage ... services, but who also cannot afford private medical ...
... Manufacturers of America (PhRMA) President and CEO Billy ... State Children,s Health Insurance Program Reauthorization Act:"President Obama,s ... Children,s Health Insurance Program (SCHIP) marks a tremendous ... and, indeed, for all Americans -- for we ...
... developed deposits, study finds , , WEDNESDAY, Feb. 4 (HealthDay ... sickened more than 50,000 kids last fall resulted in ... developing kidney problems, according to just-released Beijing research on ... in Taiwan and 10 percent of those who drank ...
... coverageWASHINGTON, Feb. 4 "This afternoon, Congress put ... the State Children,s Health Insurance Program (SCHIP). ... delivers critical help to modest-income families struggling to ... Dr. Jane L. Delgado, President and CEO of ...
... 4 , WHAT: , ... with members of the cast,of Broadway,s Tony Award-winning best musical ... 6, 2009 , WHO: , ... stories of women making,heart-healthy choices and inspiring others with their ...
... 04 February 2009 The journal Medical ... announced the winner of the 2008 David Horrobin Prize ... Jan van der Linden from the Karolinska Institute in ... risk of surgical site infection" was judged to best ...
Cached Medicine News:Health News:American Dietetic Association Commends Congress and President for Passage of State Children's Health Insurance Legislation 2Health News:PhRMA Statement on Expansion of SCHIP 2Health News:Tainted China Formula Caused High Rate of Kidney Stones in Kids 2Health News:Tainted China Formula Caused High Rate of Kidney Stones in Kids 3Health News:Final House Vote on SCHIP Delivers Peace of Mind to America's Families 2Health News:Go Red Corazon(R) 'Que nos dice el corazon?' National Casting Call Event 2
... The Sony DXC-S500 consists of 2-piece body, ... & light weight and built-in Peltier cooling devices, ... 3.5 inch LCD monitor. CCU incorporates IEEE1394 interface ... equipped with PCMCIA card slot for storing images ...
Sony DSR-20MD is the right choice If you need digital recording capability. It accepts both s-video and composite inputs....
The VISERA Multi-Specialty Digital Imaging Platform is the world's first integrated system of digital rigid, deflectable tip and flexible videoscopes for use in operating room endosurgery as well as ...
... Digital solutions for clinical image management. ... and patient-data management system derived from ... digital technology to capture, organize, and ... text data with minimum effort. Can ...
Medicine Products: